Pharmena Valuation

Q: What is the Fair Price of PHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

PHR (PLN4.93) is trading below our estimate of [[fair value]] (PLN13.23)

Is PHR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHR (PLN4.93) is trading below our estimate of fair value (PLN13.23)

Significantly Below Fair Value: PHR is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHR?

Key metric: As PHR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PHR. This is calculated by dividing PHR's market cap by their current earnings.
What is PHR's PE Ratio?
PE Ratio	1.9x
Earnings	zł28.98m
Market Cap	zł54.91m

PHR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	151.7x
Enterprise Value/EBITDA	1.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does PHR's PE Ratio compare to its peers?

The above table shows the PE ratio for PHR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	17.5x
4MS 4MASS Spólka Akcyjna	8.6x	n/a	zł154.6m
DMG Dr. Miele Cosmed Group	12.4x	n/a	zł445.4m
A900120 CXI Healthcare Technology Group	0.7x	n/a	₩21.9b
GLPL Gillette Pakistan	48.3x	n/a	PK₨4.6b
PHR Pharmena	1.9x	n/a	zł54.9m

Price-To-Earnings vs Peers: PHR is good value based on its Price-To-Earnings Ratio (1.9x) compared to the peer average (17.5x).

Price to Earnings Ratio vs Industry

How does PHR's PE Ratio compare vs other companies in the European Personal Products Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	22.2x	8.0%
PHR Pharmena	1.9x	n/a	US$13.17m

2 Companies		Estimated Growth	Market Cap
Industry Avg.	22.2x	8.0%
PHR Pharmena	1.9x	n/a	US$13.17m

No more companies

Price-To-Earnings vs Industry: PHR is good value based on its Price-To-Earnings Ratio (1.9x) compared to the European Personal Products industry average (22.2x).

Price to Earnings Ratio vs Fair Ratio

What is PHR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	1.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHR's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.